🇺🇸 US

HALO revenue, net income and debt history (Halozyme Therapeutics, Inc.)

Quick answer

Halozyme Therapeutics, Inc. (HALO) reported revenue of $1.40B and net income of $316.9M for the fiscal year ended 2025-12-31, up 37.6% from $1.02B the year before, per its 10-K filed with the SEC on 2026-02-17. Long-term debt stood at $2.14B.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$1.40B$316.9M$2.14B
2024 (FY ending 2024-12-31)$1.02B$444.1M$1.51B
2023 (FY ending 2023-12-31)$829.3M$281.6M$1.50B
2022 (FY ending 2022-12-31)$660.1M$202.1M$1.51B
2021 (FY ending 2021-12-31)$443.3M$402.7M$787.3M
2020 (FY ending 2020-12-31)$267.6M$129.1M$0.0M
2019 (FY ending 2019-12-31)$196.0M-$72.2M$383.0M
2018 (FY ending 2018-12-31)$151.9M-$80.3M$34.9M
2017 (FY ending 2017-12-31)$316.6M$63.0M$125.1M
2016 (FY ending 2016-12-31)$146.7M-$103.0M$199.2M

Related

Last updated 2026-10-16. Data only, not financial or tax advice.